About
Specialty Pharmaceuticals for Parkinson's
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Team (30)
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
2,061
By Phase
PHASE3: 2PHASE2: 2PHASE2/PHASE3: 1PHASE1: 2PHASE1/PHASE2: 2
By Status
COMPLETED: 5RECRUITING: 3TERMINATED: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06709014Lead Sponsor
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
PHASE3Recruiting
760 participants
Started: Feb 4, 2025 · Completed: Jun 30, 2028
NCT06708260Lead Sponsor
A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME
PHASE2Recruiting
60 participants
Started: Dec 12, 2024 · Completed: Feb 28, 2026
NCT06632613Lead Sponsor
Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery
PHASE2Recruiting
200 participants
Started: Nov 5, 2024 · Completed: Mar 31, 2026
NCT05686044Lead Sponsor
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
PHASE2/PHASE3Completed
351 participants
Started: Apr 1, 2023 · Completed: Feb 13, 2024
NCT05357989Lead Sponsor
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
PHASE3Completed
523 participants
Started: Aug 3, 2022 · Completed: Dec 4, 2023
Locations (1)
Headquarters
Malvern, PA, United States
Map
Loading map...